Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Magseed Pro(R)/ Sentimag(R) Gen3

NCT: NCT05142787 · RECRUITING

NCT IDNCT05142787
StatusRECRUITING
Start Date2023-03-02
Completion2028-06-30
SponsorEndomagnetics Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast

Frequently Asked Questions

What is Magseed Pro(R)/ Sentimag(R) Gen3?

Magseed Pro(R)/ Sentimag(R) Gen3 is a clinical trial registered under NCT05142787. Current status: RECRUITING.

What is the status of NCT05142787?

The current status of NCT05142787 (Magseed Pro(R)/ Sentimag(R) Gen3) is: RECRUITING.

When did Magseed Pro(R)/ Sentimag(R) Gen3 start?

Magseed Pro(R)/ Sentimag(R) Gen3 started on 2023-03-02.

Related Devices

K232865Magseed Pro Magnetic Marker SystemEndomagnetics Ltd., K153044Sentimag System, Sentimark Magnetic Marker SystermEndomagnetics Ltd., K163541Magseed Magnetic Marker SystemEndomagnetics Ltd., K173587Magseed Magnetic Marker SysttemEndomagnetics Ltd., PMA P160053Lymph node location system during sentinel biopsy procedureEndomagnetics Ltd.,

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑